Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ (3,133,994) $ (154,823)
Adjustments to reconcile net income (loss) to net cash provided by (used by) operating activities:    
Depreciation and amortization 16,755 14,084
Non-cash amortization of right of use asset 12,875 0
Gain on equipment disposal (1,500) 0
Bad debt expense 754,338 35,779
Amortization of discount on investment in account receivable (59,995) (57,755)
Gain on sale of investment in Brighter Day Health 0 (53,058)
Increase in accrued investment interest income (9,545) (1,588)
(Gain) loss on investment in securities, at fair value 56,528 (269,548)
Gain on long-term investments 0 (33,249)
Impairment on G Farma notes receivable and investments 1,688,825 0
Decrease (increase) in operating assets    
Cash in attorney trust accounts 0 314,536
Deposits on manufacturing equipment purchases 30,384 0
Accounts receivable - trade (106,785) (62,311)
Prepaid expenses and other current assets 5,486 460
Employee advances (4,054) (3,229)
Increase (decrease) in operating liabilities    
Accounts payable (35,059) (5,250)
Accrued expenses (112,243) 22,168
Deferred revenue (13,926) 97,920
Accrued salary, retirement and benefits - related party 51,085 49,539
Net cash provided by (used by) operating activities (860,825) (106.325)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from receivable - Bhang Corporation 0 1,987,099
Purchase of investment securities 0 (236,272)
Proceeds from investment securities sold 249,222 0
Proceeds from convertible notes receivable 0 4,140
Cash advanced on notes receivable (31,000) (179,000)
Proceeds from notes receivable 7,298 24,750
Deposits on equipment to be leased (18,153) (797,563)
Investment in direct financing leases (80,860) (593,958)
Proceeds from finance lease receivable 91,567 58,281
Purchase contractual interest in legal recovery (110,500) 0
Purchases of property and equipment (8,158) (17,541)
Proceeds from sale of property and equipment 1,500 0
Proceeds from sale of investment in Brighter Day Health 0 109,000
Purchase of long-term investment 0 (5,669)
Proceeds from investment in receivable 117,000 117,000
Net cash provided by (used by) investing activities 217,916 470,267
CASH FLOWS FROM FINANCING ACTIVITIES:    
Warrants converted to common stock, net of costs 0 629,204
Payment to rescind Bhang owners' common stock 0 (228,149)
Issuance of Series Q preferred shares, net of costs 0 109,985
Payments on related party payable (8,313) 0
Payments on finance lease liabilities (15,757) 0
Payments on long-term debt (44,946) (24,023)
Non-controlling interest distribution (2,524) (2,745)
Net cash provided by (used by) financing activities (71,540) 484,272
Net change in cash (714,449) 848,214
Beginning cash 1,470,574 834,190
Ending cash 756,125 1,682,404
SUPPLEMENTARY INFORMATION:    
Cash paid for interest 16,834 11,650
Cash paid for income taxes 15,070 18,870
NON-CASH INVESTING AND FINANCING TRANSACTIONS:    
Right of use assets acquired through operating lease liability 538,179 0
Right of use assets acquired through finance lease liability 179,933 0
Shareholder assumption of warrant liability 0 15,276
Bhang Corporation receivable cancelled by return of Mentor common stock 0 228,150
Convertible note receivable converted to equity in Electrum $ 0 $ 86,256